We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorWu, Qiong
dc.contributor.authorLian, Jane B.
dc.contributor.authorStein, Janet L.
dc.contributor.authorStein, Gary S.
dc.contributor.authorNickerson, Jeffrey A.
dc.contributor.authorImbalzano, Anthony N.
dc.date2022-08-11T08:10:13.000
dc.date.accessioned2022-08-23T16:59:26Z
dc.date.available2022-08-23T16:59:26Z
dc.date.issued2017-06-01
dc.date.submitted2017-07-20
dc.identifier.citationEpigenomics. 2017 Jun;9(6):919-931. doi: 10.2217/epi-2017-0034. Epub 2017 May 19. <a href="https://doi.org/10.2217/epi-2017-0034">Link to article on publisher's site</a>
dc.identifier.issn1750-192X (Linking)
dc.identifier.doi10.2217/epi-2017-0034
dc.identifier.pmid28521512
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43585
dc.description.abstractMammalian SWI/SNF enzymes are ATP-dependent remodelers of chromatin structure. These multisubunit enzymes are heterogeneous in composition; there are two catalytic ATPase subunits, BRM and BRG1, that are mutually exclusive, and additional subunits are incorporated in a combinatorial manner. Recent findings indicate that approximately 20% of human cancers contain mutations in SWI/SNF enzyme subunits, leading to the conclusion that the enzyme subunits are critical tumor suppressors. However, overexpression of specific subunits without apparent mutation is emerging as an alternative mechanism by which cellular transformation may occur. Here we highlight recent evidence linking elevated expression of the BRG1 ATPase to tissue-specific cancers and work suggesting that inhibiting BRG1 may be an effective therapeutic strategy.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28521512&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.2217/epi-2017-0034
dc.rights© Anthony N. Imbalzano.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectADAADi
dc.subjectBRG1
dc.subjectBRM
dc.subjectPFI-3
dc.subjectbreast cancer
dc.subjectcancer metabolism
dc.subjectchromatin remodeling
dc.subjectdrug transporters
dc.subjectmammalian SWI/SNF enzymes
dc.subjectBiochemistry, Biophysics, and Structural Biology
dc.subjectCancer Biology
dc.subjectCell Biology
dc.subjectGenetics and Genomics
dc.titleThe BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer
dc.typeJournal Article
dc.source.journaltitleEpigenomics
dc.source.volume9
dc.source.issue6
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1154&amp;context=peds_pp&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_pp/155
dc.identifier.contextkey10456093
refterms.dateFOA2022-08-23T16:59:26Z
html.description.abstract<p>Mammalian SWI/SNF enzymes are ATP-dependent remodelers of chromatin structure. These multisubunit enzymes are heterogeneous in composition; there are two catalytic ATPase subunits, BRM and BRG1, that are mutually exclusive, and additional subunits are incorporated in a combinatorial manner. Recent findings indicate that approximately 20% of human cancers contain mutations in SWI/SNF enzyme subunits, leading to the conclusion that the enzyme subunits are critical tumor suppressors. However, overexpression of specific subunits without apparent mutation is emerging as an alternative mechanism by which cellular transformation may occur. Here we highlight recent evidence linking elevated expression of the BRG1 ATPase to tissue-specific cancers and work suggesting that inhibiting BRG1 may be an effective therapeutic strategy.</p>
dc.identifier.submissionpathpeds_pp/155
dc.contributor.departmentBiochemistry and Molecular Pharmacology
dc.contributor.departmentPediatrics
dc.source.pages919-931


Files in this item

Thumbnail
Name:
epi_2017_0034.pdf
Size:
1.022Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© Anthony N. Imbalzano.
Except where otherwise noted, this item's license is described as © Anthony N. Imbalzano.